SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

Inclusion Criteria: * Age \>18 years * Child-Pugh score ≤ 7 * Performance status: ECOG score ≤ 2 * HCC diagnosed by biopsy or by the noninvasive criteria of the Chinese Liver Cancer Guideline 2017 * the primary HCC being unresectable (BCLC C stage/ CNLC Ⅲa-b) according to NCCN guideline * No previous therapy for HCC * at least one measurable target lesion according to RECIST 1.1 * Adequate hematopoietic function: Hemoglobin ≥ 8.5 g/dL; Absolute neutrophil count ≥ 750/mm3; Platelet count ≥ 50,000/mm3 * Serum total bilirubin ≤ 2 x ULN * Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 10 x ULN * Creatinine ≤ 1.5 x ULN * No plan for pregnancy or breast feeding. Active contraception. * Willing to give informed consent Exclusion Criteria: * Prior history to or exposure of transarterial chemoembolization, external beam radiation to liver, or sorafenib * Complete obstruction of hepatic outflow * Uncontrolled ascites of hepatic encephalopathy * Prior liver transplantation * Positive for human immunodeficiency virus (HIV) * Active gastric or duodenal ulcer * Other uncontrolled comorbidities or malignancy * Inability to give informed consent